hospitalacquir
pneumonia
hap
remain
import
caus
morbid
mortal
rang
despit
advanc
diagnosi
treatment
ventilatorassoci
pneumonia
vap
subtyp
develop
patient
mechan
ventil
least
h
togeth
second
common
frequent
nosocomi
infect
among
hospit
patient
identifi
caus
pathogen
key
antibiot
choic
differenti
diagnosi
epidemiolog
monitor
rel
preval
rate
specif
caus
pathogen
hap
vap
vari
consider
patient
popul
durat
hospit
mechan
ventil
prior
antibiot
therapi
diagnost
method
criteria
hap
often
caus
multidrug
resist
mdr
pathogen
pose
therapeut
challeng
gramposit
gramneg
bacteri
mdr
pathogen
common
patient
hap
vap
common
gramposit
bacteria
methicillinresist
staphylococcu
aureu
mrsa
vancomycinintermedi
aureu
common
gramneg
bacteria
pseudomona
aeruginosa
acinetobact
speci
enterobacteriacea
may
either
extendedspectrum
esbl
produc
carbapenemresist
includ
klebsiella
pneumonia
carbapenemas
kpc
produc
variant
interest
increas
gramneg
pathogen
recent
year
associ
higher
mortal
moreov
patient
treat
intens
care
unit
icu
mdr
pathogen
preval
increas
risk
develop
mdr
vap
regardless
risk
factor
reason
determin
frequenc
mdr
pathogen
icu
essenti
choic
antimicrobi
treatment
base
recommend
guidelin
local
andor
region
epidemiolog
data
frequenc
occurr
antimicrobi
suscept
pattern
minim
risk
inappropri
empir
antimicrobi
therapi
includ
excess
broadspectrum
use
recommend
broadspectrum
empir
antimicrobi
therapi
initi
earli
follow
deescal
soon
result
antibiot
suscept
test
avail
review
focu
vap
major
diagnost
challeng
delay
microbiolog
identif
hinder
abil
clinician
streamlin
therapi
diagnost
delay
result
excess
exposur
broadspectrum
antimicrobi
risk
perpetu
problem
antibiot
resist
effort
need
address
issu
consensu
gold
standard
diagnosi
hapvap
clinic
suspicion
vap
often
confirm
microbiolog
cultur
lower
respiratori
sampl
controversi
persist
optim
methodolog
collect
lower
respiratori
tract
sampl
diagnos
vap
obtain
lower
respiratori
tract
sampl
distal
proxim
site
narrow
spectrum
initi
empir
antimicrobi
therapi
howev
limit
evid
support
use
invas
noninvas
method
obtain
respiratori
sampl
hapvap
invas
techniqu
bronchoalveolar
lavag
bal
protect
specimen
brush
quantit
cultur
requir
qualifi
clinician
less
invas
strategi
endotrach
aspir
nasotrach
suction
lead
overidentif
bacteria
current
guidanc
american
thorac
societi
infecti
diseas
societi
america
therefor
state
limit
evid
support
invas
techniqu
obtain
respiratori
sampl
patient
hapvap
instead
recommend
noninvas
sampl
semiquantit
cultur
patient
howev
use
clinic
criteria
relianc
semiquantit
cultur
result
falseposit
vap
diagnos
unnecessari
antibiot
use
reason
european
guidelin
suggest
accuraci
could
improv
obtain
distal
sampl
quantit
cultur
base
bacteri
growth
colonyform
unit
cfu
ml
endotrach
aspir
cfuml
bal
specimen
cfuml
protect
specimen
brush
sampl
thereaft
tradit
gram
stain
cultur
antibiot
suscept
test
necessari
h
may
long
patient
treat
inappropri
empir
antimicrobi
therapi
may
suffici
emerg
carriag
carbapenemresist
bacteria
nonventil
hap
pose
sever
challeng
lower
respiratori
sampl
collect
initi
approach
start
sputum
collect
requir
coordin
patient
effort
good
qualiti
sampl
patient
expector
prescrib
nebul
sodium
chlorid
help
loosen
secret
specimen
collect
sampl
method
upper
respiratori
sampl
collect
nasopharyng
swab
np
nasal
aspir
nasal
wash
throat
swab
compar
np
swab
nasal
aspir
nasal
wash
technic
challeng
aspir
risk
practic
sever
ill
children
adult
resourcepoor
set
np
swab
prefer
method
urt
sampl
detect
virus
quantif
bateri
load
np
specimen
may
help
differenti
colon
diseas
context
pneumonia
limit
inform
avail
present
issu
exist
methodolog
led
develop
sever
altern
microbi
cultur
techniqu
achiev
rapid
accur
diagnosi
nosocomi
pneumonia
although
molecular
techniqu
develop
last
year
progress
last
decad
particularli
rapid
quantit
polymeras
chain
reaction
pcr
nucleic
acid
array
mass
spectrometri
ms
avail
improv
speed
accuraci
laboratori
result
review
intent
perform
systemat
review
exist
literatur
diagnosi
hapvap
accord
recommend
new
guidelin
hapvap
explain
difficulti
diagnosi
suggest
method
collect
respiratori
sampl
test
new
microbiolog
techniqu
present
number
rapid
molecular
test
develop
identifi
pathogen
presenc
genet
determin
antimicrobi
resist
attempt
describ
valid
use
clinic
practic
result
systemat
review
emerg
diagnost
method
hapvap
present
detail
highlight
novel
radiolog
mainli
microbiolog
approach
expedit
diagnosi
hapvap
clinician
diagnos
pneumonia
base
find
new
progress
radiolog
infiltr
least
one
clinic
featur
eg
fever
leukocytosi
worsen
oxygen
purul
tracheal
secret
approach
high
sensit
low
specif
diagnos
vap
normal
chest
radiograph
may
complet
exclud
pneumonia
although
chest
radiographi
wide
use
despit
limit
comput
tomographi
ct
remain
gold
standard
ct
chest
advantag
detect
subtl
lung
infiltr
particularli
patient
chronic
obstruct
pulmonari
diseas
often
miss
chest
radiographi
anoth
noninvas
option
pointofcar
lung
ultrasound
gain
popular
icu
recent
year
compar
method
lung
ultrasound
free
radiat
use
bedsid
pregnant
woman
allow
dynam
evalu
accur
chest
radiographi
detect
pleural
effus
take
less
time
although
visual
consolid
region
lineararboresc
dynam
airbronchogram
good
specif
visual
subpleur
consolid
good
sensit
limit
specif
experienc
hand
normal
lung
ultrasound
exclud
vap
lung
ultrasound
also
use
monitor
infiltr
activ
treatment
current
clinic
approach
pneumonia
surveil
earli
detect
convent
culturebas
microbiolog
critic
ill
patient
inadequ
target
antibiot
treatment
stewardship
molecular
diagnosi
hospitalacquir
pneumonia
ventilatorassoci
pneumonia
provid
accuraci
rapid
pathogen
detect
rapid
microbiolog
diagnost
includ
multiplex
polymeras
chain
reaction
nucleic
acid
amplif
mass
spectrometri
fluoresc
microscopybas
technolog
exhal
breath
biomark
includ
volatil
organ
compound
repres
promis
approach
futur
molecular
test
help
detect
multipl
bacteri
pathogen
simultan
novel
approach
need
distinguish
infect
colon
may
includ
use
quantit
method
identif
discrimin
cutoff
level
anticip
studi
molecular
test
focu
method
requir
help
interpret
signific
posit
result
applic
clinic
practic
research
agenda
place
greater
focu
nextgener
sequenc
microbiom
research
gener
rapid
method
detect
respiratori
pathogen
base
immunolog
molecular
techniqu
immunolog
method
use
antigen
detect
immunofluoresc
enzym
immunoassay
immunochromatographi
direct
indirect
immunofluoresc
wide
use
detect
respiratori
virus
limit
qualit
natur
limit
sensit
inabl
distinguish
infect
virus
immunochromatograph
urinari
antigen
test
pneumonia
sensit
specif
urinari
antigen
test
may
also
appli
pleural
fluid
serum
sampl
albeit
lower
sensit
commonli
avail
legionella
urinari
antigen
assay
sensit
around
serogroup
infect
approxim
infect
us
europ
detect
serotyp
advanc
urin
antigen
detect
test
patient
pneumonia
mean
new
kit
show
greater
sensit
detect
pneumonia
l
pneumophila
singl
test
detect
pneumococc
serotyp
mention
urin
antigen
test
realli
valid
adult
paediatr
patient
use
molecular
techniqu
especi
nucleicacidbas
amplif
method
mani
advantag
convent
method
provid
high
sensit
specif
identifi
respiratori
pathogen
possibl
detect
multipl
pathogen
potenti
establish
antimicrobi
resist
pattern
ideal
rapid
molecular
diagnost
platform
would
also
provid
pointofcar
test
possibl
direct
identif
quantif
pathogen
load
singl
clinic
sampl
main
advantag
method
convent
techniqu
bacteri
respiratori
viral
identif
basi
molecular
assay
includ
pcr
dna
amplif
reversetranscript
pcr
nucleic
acidsequencebas
amplif
nucleic
acidbas
technolog
nat
sever
advantag
diagnost
tool
potenti
detect
low
level
known
pathogen
clinic
specimen
depend
viabil
target
microb
provid
result
within
clinic
use
time
frame
nat
may
also
quantifi
target
organ
densiti
case
respiratori
virus
strain
type
high
sensit
specif
make
method
choic
test
respiratori
virus
respiratori
virus
commonli
detect
nat
larg
multiplex
panel
includ
influenza
b
virus
respiratori
syncyti
viru
parainfluenza
virus
human
metapneumoviru
human
rhinovirus
enterovirus
adenovirus
human
bocaviru
sever
coronavirus
eg
bacteri
target
bordetella
pertussi
mycoplasma
pneumonia
chlamydophila
pneumonia
also
includ
commerci
multiplex
respiratori
viru
pcr
similar
approach
use
detect
bacteri
pathogen
complic
respiratori
viral
infect
given
coinfect
critic
ill
patient
influenza
increas
p
nat
use
patient
hapvap
recent
assay
allow
multiplex
viral
target
good
sensit
includ
use
pcr
melt
curv
analysi
filmarray
ausdiagnost
microcapillari
electrophoresi
seeplex
respifind
iceplex
microspher
hybrid
associ
flow
cytomet
detect
solid
phase
hybrid
infin
ngen
verigen
icub
esensor
pcr
coupl
electrospray
ionizationm
esim
plexid
varieti
new
platform
develop
speed
pathogen
identif
includ
sensit
test
assay
design
organ
identif
includ
genexpert
allinon
platform
design
pointofcar
test
assay
turnaround
time
two
hour
thu
result
avail
fast
enough
affect
empir
treatment
choic
genexpert
system
detect
aureu
mrsa
coloni
directli
blood
cultur
nasal
skin
soft
tissu
swab
genxpert
use
autom
microfluid
procedur
depend
realtim
pcr
aureu
mrsa
bd
geneohm
mrsa
use
realtim
pcr
fluorogen
target
hybrid
probe
genexpert
assay
influenza
b
compar
two
commerci
avail
rapid
antigen
test
shown
excel
sensit
b
respect
specif
use
genexpert
lower
respiratori
tract
sampl
patient
suspect
vap
high
sensit
moder
specif
compar
bacteri
cultur
detect
saureu
bd
geneohm
assay
use
realtim
pcr
fluorogen
target
hybrad
probe
design
detect
aureu
mrsa
respiratori
specimen
rapid
molecular
assay
detect
aureu
major
clinic
benefit
determin
aureu
colon
statu
filmarray
respiratori
panel
produc
biofir
salt
lake
citi
ut
array
integr
nucleic
acid
extract
nest
pcr
detect
data
analysi
singleus
pouch
first
assay
approv
food
drug
administr
fda
qualit
detect
viral
bacteri
nucleic
acid
target
nasopharyng
swab
specimen
filmarray
respiratori
panel
detect
viral
target
three
bacteri
speci
b
pertussi
c
pneumonia
pneumonia
typic
associ
pneumonia
tabl
assay
turnaround
time
approxim
hour
appli
direct
respiratori
specimen
includ
bal
specimen
mechan
ventil
patient
also
given
multifoc
natur
vap
even
minib
sampl
obtain
blindli
without
use
bronchoscopi
effect
recent
filmarray
respiratori
panel
employ
demonstr
hap
episod
associ
respiratori
viru
infect
alon
concomit
viral
bacteri
infect
filmarray
respiratori
panel
recent
extend
includ
common
respiratori
pathogen
includ
gramposit
bacteria
gramneg
bacteria
candida
speci
global
sensit
specif
compar
convent
microbiolog
techniqu
lightcycl
septifast
realtim
multiplex
pcr
assay
identifi
bacteri
fungal
speci
account
case
bacteremiafungaemia
assay
requir
lengthi
dna
extract
time
hour
optim
pointof
care
test
yet
pilot
studi
baudel
et
al
suggest
multiplex
pcr
perform
bal
fluid
critic
ill
patient
could
improv
rate
pathogen
detect
pneumonia
compar
direct
examin
cultur
p
pathogen
identif
rate
provid
multiplex
pcr
modifi
prior
antibiot
treatment
vs
nonsignific
remain
superior
cultur
p
matrixassist
laser
desorpt
ioniz
maldi
timeofflight
tof
mass
spectrometri
ms
power
microbiolog
tool
gradual
implement
pathogen
identif
conjunct
convent
method
malditof
ms
proteinpeptidebas
diagnost
ms
method
reli
measur
molecular
mass
cellular
protein
determin
uniqu
global
protein
profil
characterist
pathogen
studi
bacteri
isol
malditof
ms
show
sensit
specif
sampl
identif
compar
convent
system
take
minisol
identif
cost
less
current
method
genet
sequenc
appli
identifi
pathogen
monitor
antimicrobi
resist
type
strain
simpli
defin
microarray
collect
microscop
featur
eg
dna
probe
target
molecul
produc
quantit
gene
express
qualit
diagnost
data
recent
develop
assay
develop
expedit
antimicrobi
resist
test
includ
verigen
nanospher
system
multiplex
nucleic
acid
detect
assay
use
clinic
laboratori
identifi
pathogen
detect
resist
gene
posit
blood
cultur
antimicrobi
resist
marker
identifi
within
h
posit
blood
cultur
use
verigen
assay
bacteremia
associ
reduc
length
stay
reduc
mortal
improv
time
optim
antimicrobi
therapi
septicyt
diagnost
tool
infecti
diseas
host
gene
express
approv
fda
although
short
assay
time
h
gener
consid
complex
lengthi
routin
clinic
use
septicyt
measur
differenti
express
four
gene
valid
observ
studi
among
adult
children
suspect
sepsi
vapchip
assay
assay
base
brapidarraypcr
technolog
directli
target
respiratori
pathogen
resist
gene
clinic
respiratori
specimen
roisin
et
al
evalu
diagnost
perform
assay
detect
character
etiolog
agent
nosocomi
pneumonia
use
respiratori
sampl
patient
admit
icu
bacteri
identif
vapchip
sensit
specif
possess
consider
multiplex
capac
use
detect
unlimit
number
gene
within
reaction
mixtur
gramneg
mdr
pathogen
typic
caus
vap
gene
respons
resist
antibiot
case
microarraybas
assay
check
kpcesbl
checkpoint
use
identifi
bla
gene
present
microbi
isol
identifi
bacteria
provid
inform
mechan
antimicrobi
resist
assay
take
hour
sever
studi
highlight
abil
assay
detect
bla
gene
correspond
tem
shv
ctxm
kpc
report
high
sensit
specif
studi
endimiani
et
al
exampl
sensit
specif
check
kpcesbl
assay
compar
convent
microbiolog
suscept
test
among
gramneg
strain
rang
followup
studi
fishbain
et
al
use
water
lysi
step
platform
sensit
specif
blood
cultur
sampl
contain
esbland
kpcproduc
pathogen
pcresim
emerg
technolog
capabl
identifi
nearli
known
human
pathogen
either
microbi
isol
directli
clinic
specimen
broadrang
amplif
follow
detect
mix
amplicon
method
identifi
genet
evid
known
unknown
pathogen
start
wolk
et
al
identifi
presenc
meca
gene
show
good
correl
mrsa
phenotyp
also
identif
toxin
gene
pvl
pcresim
correl
independ
pcr
analys
gene
recent
malditof
msbase
assay
shown
use
detect
resist
differ
antibiot
includ
carbapenem
also
pcresim
current
fastest
msbase
method
diagnosi
produc
result
within
hour
directli
clinic
specimen
therebi
bypass
need
bacteri
cultur
tabl
multicent
observ
studi
novel
cultureindepend
pcresim
method
test
patient
among
patient
pneumonia
cultur
posit
pcresim
neg
case
addit
neg
case
thu
pcresim
shown
sensit
specif
neg
predict
valu
h
sampl
acquisit
independ
clinic
analysi
result
suggest
pcresim
could
alter
treatment
mani
case
rapid
autom
microscopi
addit
autom
microscopi
method
identificationantibiot
suscept
test
system
acceler
diagnost
inc
develop
use
genom
phenotyp
technolog
provid
pathogen
identif
antimicrobi
suscept
rapid
manner
research
perform
pilot
clinic
trial
use
prototyp
acceler
pheno
tucson
az
rapid
autom
microscopi
system
detect
potenti
mdr
pathogen
minib
surveil
sampl
mechan
ventil
adult
risk
vap
microscopi
reveal
microbiolog
posit
sampl
organ
n
neg
sampl
compar
cultur
sensit
specif
specif
rapidli
detect
carbapenem
resist
k
pneumonia
present
predict
resist
attribut
kpc
carbapenemas
fluoresc
insitu
hybrid
autom
microscopi
tool
base
fluoresc
insitu
hybrid
fish
also
offer
interest
methodolog
rapid
identif
antibiot
suscept
test
blood
respiratori
sampl
fish
techniqu
base
fluoresc
label
oligonucleotid
probe
bind
complementarili
specif
target
ribosom
rna
sequenc
bacteria
yeast
microorgan
fish
use
detect
pathogen
difficult
time
consum
identifi
tradit
method
especi
one
speci
present
occur
polymicrobi
infect
typic
vap
instanc
metzger
et
al
observ
high
rate
concord
fish
microscopi
convent
microbiolog
techniqu
detect
organ
respiratori
specimen
bal
contain
target
speci
diagnost
threshold
similarli
techniqu
use
microbiolog
surveil
method
sensit
specif
compar
standard
respiratori
cultur
test
biorad
test
biorad
new
chromogen
test
allow
rapid
detect
resist
among
enterobacteriacea
test
may
perform
either
directli
enterobacteriacea
isol
coloni
bacteri
pellet
posit
blood
cultur
urin
greek
studi
test
exhibit
excel
sensit
specif
detect
esc
nonsuscept
clinic
isol
harbour
mainli
extendedspectrum
esbl
kpcand
ndmtype
enzym
recent
studi
garnier
et
al
evalu
tool
earli
escal
deescal
antimicrobi
therapi
gramneg
bacteri
infect
hap
result
show
rate
appropri
antimicrobi
therapi
signific
reduct
time
antimicrobi
chang
vs
h
anoth
studi
test
detect
sensit
presenc
k
pneumonia
spike
steril
bronchial
aspir
sampl
ba
upon
two
gnb
per
field
upon
microscop
gram
stain
examin
author
conclud
accur
tool
esblpegnb
detect
directli
ba
exhal
breath
analysi
promis
noninvas
method
rapidli
differenti
healthi
individu
diseas
produc
volatil
organ
compound
voc
vocguid
microbiolog
identif
report
use
convent
ga
chromatographym
novel
nanocomposit
sensor
array
enos
among
ventil
patient
icu
schnabel
et
al
found
subset
voc
correctli
discrimin
vapposit
vapneg
patient
sensit
specif
respect
may
et
al
also
describ
novel
strategi
rapid
diagnosi
vap
use
exhal
breath
condens
fluid
heatmoistur
exchang
provid
test
substrat
identifi
bacteri
dna
pcr
show
excel
concord
pathogen
identif
pcr
exhal
breath
condens
fluid
pathogen
isol
bal
fluid
addit
found
increas
dna
load
among
serial
exhal
breath
condens
fluid
sampl
predict
subsequ
vap
util
voc
produc
respiratori
pathogen
therefor
great
interest
particularli
noninvas
earli
diagnost
tool
hapvap
serial
voc
sampl
simpl
acquir
may
allow
preemptiv
target
prevent
treatment
earli
vap
tracheobronch
larg
multicent
european
studi
progress
evalu
util
perform
vocguid
diagnosi
vap
breathdx
ntr
adopt
novel
diagnost
techniqu
remain
rel
low
molecular
techniqu
direct
suscept
test
use
elig
respiratori
sampl
among
patient
potenti
vap
spanish
hospit
thu
urgent
need
studi
conduct
new
molecular
technolog
especi
patient
vap
gold
standard
method
diagnos
vap
must
remain
bal
sampl
comparison
made
endotrach
aspir
convent
method
howev
done
knowledg
bal
sampl
particularli
challeng
work
contamin
purul
debri
respiratori
epitheli
inflammatori
cell
may
render
sampl
difficult
assay
nucleic
acid
amplif
proteom
techniqu
addit
studi
need
evalu
clinic
util
rapid
microorgan
identif
via
molecular
method
bal
fluid
vap
prepostimplement
studi
mok
et
al
report
rapid
microorgan
identif
via
malditof
ms
decreas
length
icu
stay
analyz
bal
fluid
p
addit
need
research
optim
assay
ideal
pointofcar
test
achiev
rapid
reliabl
aetiolog
diagnos
hapvap
import
field
ongo
research
develop
market
technic
sophist
method
last
decad
start
transform
process
microbiolog
identif
reli
blood
cultur
much
rapid
process
perform
directli
specimen
reli
nucleic
acid
amplif
includ
ms
realtim
autom
microscopi
technolog
abil
identifi
organ
also
detect
resist
mechan
start
empir
antimicrobi
therapi
could
essenti
control
spread
mdr
especi
context
epidem
howev
new
medic
technolog
need
properli
valid
clinic
practic
major
reason
slow
uptak
accept
recent
develop
novel
assay
diagnosi
respiratori
infect
lack
commerci
assay
nat
sensit
gold
standard
cell
cultur
method
diagnosi
respiratori
virus
specif
antigen
detect
test
includ
immunochromatograph
immunofluoresc
assay
howev
new
technolog
also
import
limit
unabl
differenti
colon
infect
could
highli
problemat
mechan
ventil
patient
also
unabl
give
true
suscept
pattern
respons
pathogen
exampl
although
peptid
nucleic
acid
fish
pnafish
provid
rapid
identif
suscept
inform
method
limit
abil
identifi
rel
organ
labor
intens
current
formul
comparison
malditof
identifi
mani
organ
compar
straightforward
method
although
nucleic
acid
extractionindepend
assay
malditof
ms
microarray
lamp
promis
current
limit
limit
rang
organ
detect
among
main
drawback
new
techniqu
reli
qualit
evalu
subject
contamin
risk
cost
often
prohibit
often
lack
valid
one
approach
help
distinguish
infect
contamin
colon
quantifi
microbi
load
molecular
method
involv
molecular
diagnost
test
develop
pneumonia
need
look
beyond
simpl
detect
specif
known
pathogen
provid
mean
interpret
clinic
signific
posit
result
accur
distinguish
colon
infect
use
quantit
cutoff
number
cfu
recommend
eg
cfuml
howev
studi
still
need
confirm
efficaci
safeti
costeffect
use
tool
initi
antibiot
select
icu
promis
technolog
electron
nose
use
ga
chromatographi
identifi
presenc
vap
specif
pathogen
realtim
exhal
ga
analysi
ventil
potenti
lead
earlier
accur
initi
therapi
voc
signatur
effect
differenti
patient
colon
vap
also
predict
diseas
cours
may
supersed
current
avail
method
less
sensit
specif
earli
detect
vap
eg
chest
radiograph
ct
imag
sputum
cytolog
inflammatori
marker
ga
exchang
analysi
anticip
bodi
evid
expand
find
welldesign
clinic
research
undertak
focus
evalu
perform
novel
assay
assay
optim
routin
clinic
use
signific
advanc
made
expedit
diagnosi
goaldirect
treatment
hapvap
two
main
technolog
advanc
ongo
first
develop
pointofcar
test
miniatur
portabl
machin
allow
rapid
test
bedsid
second
develop
new
method
analysi
gene
express
genom
rna
activ
transcriptom
protein
product
proteom
lipid
lipidom
metabolit
metabolom
addit
acceler
time
diagnosi
cultur
pathogen
realtim
metagenom
hold
potenti
identifi
pathogen
grown
cultur
nextgener
sequenc
allow
quicker
cheaper
dna
rna
sequenc
permit
sanger
sequenc
pcr
ribosom
rna
genebas
sequenc
approach
metagenom
approach
identifi
bacteria
virus
fungi
alik
rrna
gene
sequenc
analysi
standard
method
bacteri
taxonomi
identif
base
detect
sequenc
differ
polymorph
hypervari
region
rrna
gene
present
bacteria
amplif
gene
pcr
assay
result
amplif
bacteria
sampl
although
gene
sequenc
use
explor
microbiom
ventil
patient
morri
et
al
use
bal
sampl
assess
diagnost
accuraci
two
ribosom
rna
gene
pcr
assay
rapid
exclus
vap
within
h
nguyen
et
al
appli
modern
proteom
approach
identifi
presenc
lactotransferrin
bal
sampl
discrimin
patient
vap
acut
lung
injuri
addit
kothari
et
al
report
overexpress
tumor
necrosi
factor
alpha
gene
associ
increas
incid
sever
sepsi
septic
shock
caus
includ
pneumonia
sequenc
techniqu
effect
narrow
microbiom
divers
set
longer
mechan
ventil
durat
use
predict
futur
vap
onset
domin
bacteri
taxa
emerg
work
need
streamlin
bioinformat
analysi
metagenom
sequenc
data
approach
scale
test
clinic
context
novel
rapid
techniqu
molecular
dna
quantif
eg
droplet
digit
nanorod
pcr
may
prove
use
adjunct
help
clinician
discrimin
health
contamin
colon
infect
discoveri
technolog
bacteri
immun
system
pathogen
usag
effici
tool
make
target
chang
genom
led
huge
revolut
basic
biolog
research
develop
cluster
regularli
interspac
short
palindrom
repeat
crispr
system
revolution
field
gene
edit
thu
facilit
effici
genom
edit
creation
target
doublestrand
break
almost
organ
cell
type
implement
crisprca
system
increas
number
avail
technolog
altern
studi
gene
function
thu
enabl
gener
crisprbas
diseas
model
crispr
tool
allow
research
edit
gene
precis
easili
quickli
har
mechan
alreadi
exist
bacteria
improv
urgent
need
variou
aspect
includ
system
precis
deliveri
control
outcom
repair
process
recent
discoveri
lung
microbiom
provid
new
insight
pathogenesi
pneumonia
base
interact
multipl
microorgan
although
time
nextgener
sequenc
becom
standard
tool
diagnost
laboratori
technolog
may
provid
valuabl
insight
microbi
ecolog
lung
health
diseas
therebi
improv
understand
pathogenesi
pneumonia
